Core Viewpoint - Allogene Therapeutics is actively participating in the Citi's 2025 Biopharma Back to School Summit, showcasing its commitment to advancing allogeneic CAR T products for cancer and autoimmune diseases [1] Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, focusing on the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune diseases [2] - The company aims to create a pipeline of "off-the-shelf" CAR T cell product candidates, providing readily available cell therapy on-demand, more reliably, and at greater scale to a larger patient population [2] Investor Relations - The company will provide webcasts of the investor conference, with replays available on its website for approximately 30 days [1]

Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [4] - The company aims to provide "off-the-shelf" CAR T cell product candidates that are readily available, reliable, and scalable for patient treatment [4] Upcoming Events - Allogene Therapeutics will report its second quarter 2025 financial results and provide a business update on August 13, 2025, after market close [1] - A live audio webcast and conference call will follow the announcement at 2:00 p.m. PT/5:00 p.m. ET [1] Webcast Information - The listen-only webcast will be available on the company's website under the Investors tab in the News and Events section, with a replay accessible for approximately 30 days [2] - Registration is required for those who wish to ask questions during the conference call, and participants will receive a personal PIN upon registration [3]

Core Viewpoint - Allogene Therapeutics, Inc. is set to report its first quarter 2025 financial results and provide a business update on May 13, 2025, followed by a live audio webcast and conference call [1] Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, focusing on the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [4] - The company aims to create a pipeline of "off-the-shelf" CAR T cell product candidates to deliver cell therapy on-demand, more reliably, and at greater scale to patients [4] Conference Call Details - The conference call will take place at 2:00 p.m. PT/5:00 p.m. ET, and a listen-only webcast will be available on the company's website [1][2] - Registration is required for those who wish to ask questions during the conference call, and participants will receive a personal PIN upon registration [3]